Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.

GLP-1/glucagon receptor co-agonism for treatment of obesity

Open access

Abstract

Over a relatively short period, obesity and type 2 diabetes have come to represent a large medical and economic burden to global societies. The epidemic rise in the prevalence of obesity has metabolic consequences and is paralleled by an increased occurrence of other diseases, such as diabetes, cancer and cardiovascular complications. Together, obesity and type 2 diabetes constitute one of the more preventable causes of premature death and the identification of novel, safe and effective anti-obesity drugs is of utmost importance. Pharmacological attempts to treat obesity have had limited success, with notable adverse effects, rendering bariatric surgery as the only current therapy for substantially improving body weight. Novel unimolecular, multifunctional peptides have emerged as one of the most promising medicinal approaches to enhance metabolic efficacy and restore normal body weight. In this review, we will mainly focus on the discovery and translational relevance of dual agonists that pharmacologically function at the receptors for glucagon and glucagon-like peptide-1. Such peptides have advanced to clinical evaluation and inspired the pursuit of multiple related approaches to achieving polypharmacy within single molecules.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-017-4354-8

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Metabolic actions of GLP-1R agonists and GcgR agonists on key organs (brain, BAT, adipose tissue, muscle, liver, pancreas and circulation) regulating energy and glucose homeostasis and changes in metabolic variables. FAO, fatty acid oxidation; GSIS, glucose-stimulated insulin secretion
Fig. 1 Metabolic actions of GLP-1R agonists and GcgR agonists on key organs (brain, BAT, adipose tissue, muscle, liver, pancreas and circulation) regulating energy and glucose homeostasis and changes in metabolic variables. FAO, fatty acid oxidation; GSIS, glucose-stimulated insulin secretionCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 97 references

Research works printed but not linked: 2

  1. Roglic G, World Health Organization (2016) Global report on diabetes. World Health Organization, Geneva
  2. Lao J, Hansen BC, Dimarchi R, Pocai A (2013) Effect of GLP1R/GCGR dual agonist in monkeys. Diabetes 62:A257–A257

Cited by

See all 188

Metadata

Authors
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H.
Affiliations
  • Helmholtz Munich (DE)
  • Indiana University Bloomington (US)
Corresponding author
  • DiMarchi, Richard D.
  • Tschöp, Matthias H.
Venue
Diabetologia
Published
2017-07-21
Volume
60
Issue
10
Pages
1851-1861
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2737611067
Cited by
175
References
97
Citations by year
2026: 19 · 2025: 15 · 2024: 13 · 2023: 22 · 2022: 15 · 2021: 23 · 2020: 17 · 2019: 25 · 2018: 23 · 2017: 2
FWCI
2.36
Type
journal article
Language
en
Open access
Locations
  • Diabetologia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • mediaTUM (Technical University of Munich) (submittedVersion)
  • Site cant be reached (submittedVersion, other-oa)
Funders
  • Alexander von Humboldt-Stiftung
  • Lundbeckfonden (R210-2015-4001)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
GLP-1 receptor, glucagon receptor, dual agonist, obesity, type 2 diabetes, anti-obesity drugs, peptide therapeutics, polypharmacy, bariatric surgery, weight loss
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Humans, Obesity, Receptors, Glucagon, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1/glucagon receptor co-agonism for treatment of obesity. https://app.cochat.ai/papers/10.1007/s00125-017-4354-8
The paper
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017). GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia. https://doi.org/10.1007/s00125-017-4354-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.